Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imunon ( (IMNN) ) has shared an update.
On August 27, 2025, Imunon, Inc. announced that it has regained compliance with Nasdaq’s $1.00 minimum closing bid price requirement, ensuring continued listing on the Nasdaq Capital Market. This development, alongside a recent 15% stock dividend and successful Phase 2 trial results for its DNA-based immunotherapy IMNN-001, reflects the company’s confidence in its clinical pipeline and commitment to rewarding investors. The company has also initiated its Phase 3 OVATION 3 trial in North America, further advancing its innovative TheraPlas® technology platform.
The most recent analyst rating on (IMNN) stock is a Buy with a $210.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that leverage the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases. The company is advancing its non-viral DNA technology through two main modalities: TheraPlas® for gene-based delivery of cytokines and therapeutic proteins in solid tumors, and PlaCCine® for gene delivery of viral antigens to elicit strong immunological responses. IMUNON’s lead clinical program, IMNN-001, targets advanced ovarian cancer and has shown promising results in clinical trials.
Average Trading Volume: 347,382
Technical Sentiment Signal: Sell
Current Market Cap: $15.73M
For a thorough assessment of IMNN stock, go to TipRanks’ Stock Analysis page.